Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Polt

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Pharmacology, Biochemistry, and Behavior|March 5, 2015
The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependenceGlenn W Stevenson, Amy Luginbuhl, Catherine Dunbar, et al.
Frontiers in Cardiovascular Medicine|March 23, 2026
A novel angiotensin(1-7) agonist, PNA5, reduces ischemic reperfusion injury and cardiac dysfunctionChristina Hoyer-Kimura, Meredith Hay, Methawasin Methajit, et al.
Chemical Biology & Drug Design|August 2, 2011
Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environmentsLarisa Yeomans, Dhanasekaran Muthu, John J Lowery, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 3, 2019
A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory DysfunctionMeredith Hay, Robin Polt, Michael L Heien, et al.
Aging and Disease|October 10, 2023
PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and DementiaChristina Hoyer-Kimura, Meredith Hay, John P Konhilas, et al.
BMC Research Notes|March 14, 2020
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent modelMitchell J Bartlett, Lisa Y So, Lajos Szabò, et al.
Journal of Surfactants and Detergents|July 26, 2021
Biodegradability and Toxicity of Cellobiosides and MelibiosidesDavid E Hogan, Fei Tian, Scott W Malm, et al.
International Journal of Molecular Sciences|December 30, 2020
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced DyskinesiaMitchell J Bartlett, Omar S Mabrouk, Lajos Szabò, et al.
Psychopharmacology|January 9, 2020
Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administrationGlenn W Stevenson, Denise Giuvelis, James Cormier, et al.
Experimental Neurology|August 17, 2024
The angiotensin (1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammationKelsey Bernard, Jesus A Mota, Paige Wene, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Pharmacology, Biochemistry, and Behavior|March 5, 2015
The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependenceGlenn W Stevenson, Amy Luginbuhl, Catherine Dunbar, et al.
Frontiers in Cardiovascular Medicine|March 23, 2026
A novel angiotensin(1-7) agonist, PNA5, reduces ischemic reperfusion injury and cardiac dysfunctionChristina Hoyer-Kimura, Meredith Hay, Methawasin Methajit, et al.
Chemical Biology & Drug Design|August 2, 2011
Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environmentsLarisa Yeomans, Dhanasekaran Muthu, John J Lowery, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 3, 2019
A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory DysfunctionMeredith Hay, Robin Polt, Michael L Heien, et al.
Aging and Disease|October 10, 2023
PNA5, A Novel Mas Receptor Agonist, Improves Neurovascular and Blood-Brain-Barrier Function in a Mouse Model of Vascular Cognitive Impairment and DementiaChristina Hoyer-Kimura, Meredith Hay, John P Konhilas, et al.
BMC Research Notes|March 14, 2020
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent modelMitchell J Bartlett, Lisa Y So, Lajos Szabò, et al.
Journal of Surfactants and Detergents|July 26, 2021
Biodegradability and Toxicity of Cellobiosides and MelibiosidesDavid E Hogan, Fei Tian, Scott W Malm, et al.
International Journal of Molecular Sciences|December 30, 2020
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced DyskinesiaMitchell J Bartlett, Omar S Mabrouk, Lajos Szabò, et al.
Psychopharmacology|January 9, 2020
Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administrationGlenn W Stevenson, Denise Giuvelis, James Cormier, et al.
Experimental Neurology|August 17, 2024
The angiotensin (1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammationKelsey Bernard, Jesus A Mota, Paige Wene, et al.
Pageof 6